Analysts Anticipate INmune Bio Inc (NASDAQ:INMB) Will Announce Earnings of -$0.19 Per Share

Share on StockTwits

Wall Street brokerages forecast that INmune Bio Inc (NASDAQ:INMB) will post earnings of ($0.19) per share for the current quarter, Zacks reports. Zero analysts have made estimates for INmune Bio’s earnings. The firm is scheduled to announce its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that INmune Bio will report full-year earnings of ($0.75) per share for the current financial year. For the next year, analysts forecast that the firm will report earnings of ($0.75) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that follow INmune Bio.

Separately, Maxim Group set a $13.00 price objective on shares of INmune Bio and gave the company a “buy” rating in a report on Monday.

In related news, major shareholder Linda F. Powers acquired 61,667 shares of the firm’s stock in a transaction on Wednesday, May 8th. The shares were purchased at an average cost of $9.00 per share, for a total transaction of $555,003.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman Raymond Joseph Tesi acquired 11,100 shares of the firm’s stock in a transaction on Thursday, May 2nd. The stock was bought at an average price of $9.90 per share, for a total transaction of $109,890.00. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 87,767 shares of company stock worth $769,893.

Shares of NASDAQ:INMB traded down $0.23 on Friday, hitting $10.50. The company had a trading volume of 2,479 shares, compared to its average volume of 15,817. INmune Bio has a 1-year low of $7.00 and a 1-year high of $11.50.

About INmune Bio

INmune Bio Inc, a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood.

Featured Article: Fundamental Analysis – How It Helps Investors

Get a free copy of the Zacks research report on INmune Bio (INMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Financial Analysis: Hi-Crush  and Its Competitors
Financial Analysis: Hi-Crush and Its Competitors
Northern Technologies International  Shares Scheduled to Split on Monday, July 1st
Northern Technologies International Shares Scheduled to Split on Monday, July 1st
Q2 2019 EPS Estimates for Consol Energy Inc  Reduced by Analyst
Q2 2019 EPS Estimates for Consol Energy Inc Reduced by Analyst
Werner Enterprises Sees Unusually High Options Volume
Werner Enterprises Sees Unusually High Options Volume
Insider Selling: Investec plc  Insider Sells 7,897 Shares of Stock
Insider Selling: Investec plc Insider Sells 7,897 Shares of Stock
Powell Industries  Receiving Neutral Media Coverage, Report Finds
Powell Industries Receiving Neutral Media Coverage, Report Finds


© 2006-2019 Ticker Report